The global NGS-based RNA-sequencing market is experiencing exponential growth. Valued at USD 3.74 billion in 2024, it is expected to reach USD 4.49 billion in 2025 and surge to approximately USD 23.52 billion by 2034, growing at a CAGR of 20.1% from 2025 to 2034.
This expansion is fueled by advancements in next-generation sequencing (NGS) technologies, reduced sequencing costs, and a surge in applications across clinical diagnostics, precision medicine, and biomedical research. The increasing need to study gene expression patterns, identify mutations, and develop personalized treatments is driving demand, particularly in Asia-Pacific, which is emerging as the fastest-growing region.
North America remains dominant, capturing 48% of the market share in 2024, while the mRNA sequencing segment leads the market with a 41% revenue share.
Below, we explore the key companies shaping this market’s trajectory, highlighting their contributions, products, and financial strength.
1. Illumina, Inc.
About: Illumina, a global leader in DNA sequencing and array-based technologies, is headquartered in San Diego, California. The company has been pivotal in advancing genomic research worldwide.
Products: Notable offerings include the NovaSeq series, NextSeq systems, and RNA Prep kits for transcriptomic applications.
Market Cap: Approx. USD 26 billion (as of 2025).
2. Thermo Fisher Scientific
About: Based in Waltham, Massachusetts, Thermo Fisher is a multinational biotechnology leader specializing in analytical instruments and reagents.
Products: Their Ion Torrent NGS platforms and RNA sequencing solutions are widely adopted in research and clinical labs.
Market Cap: Over USD 230 billion.
3. Oxford Nanopore Technologies
About: This UK-based firm is known for its portable and scalable sequencing technologies enabling real-time RNA analysis.
Products: MinION and PromethION devices cater to both field-based and high-throughput sequencing needs.
Market Cap: Approximately USD 3 billion.
4. Pacific Biosciences (PacBio)
About: Headquartered in Menlo Park, California, PacBio is renowned for its high-accuracy long-read sequencing technologies.
Products: Sequel II systems support comprehensive RNA-seq for isoform discovery and full-length transcript analysis.
Market Cap: Around USD 1.2 billion.
5. Agilent Technologies
About: A global leader in life sciences, Agilent focuses on analytical instrumentation and laboratory solutions.
Products: Provides RNA-Seq library preparation kits and bioanalyzers for RNA quality assessment.
Market Cap: Roughly USD 35 billion.
6. QIAGEN
About: QIAGEN is a Dutch-German company specializing in sample preparation and assay technologies.
Products: Their QIAseq RNA sequencing kits and bioinformatics tools simplify transcriptomics workflows.
Market Cap: Estimated at USD 9 billion.
7. Takara Bio Inc.
About: Based in Japan, Takara Bio offers innovative molecular biology solutions to researchers worldwide.
Products: Known for SMARTer RNA-seq kits enabling low-input and single-cell RNA sequencing.
Market Cap: Approximately USD 3 billion.
8. 10x Genomics
About: A pioneer in single-cell and spatial genomics, 10x Genomics is based in Pleasanton, California.
Products: Their Chromium platform is widely used for single-cell RNA-seq studies.
Market Cap: Around USD 6 billion.
9. BGI Genomics
About: Based in China, BGI Genomics is a leading provider of genomic sequencing services and solutions globally.
Products: Offers RNA sequencing services using their proprietary DNBSEQ technology.
Market Cap: Close to USD 2 billion.
10. PerkinElmer (Revvity)
About: PerkinElmer (now Revvity) delivers innovative solutions for diagnostics and life sciences research.
Products: Provides RNA-seq workflow solutions and automation platforms for high-throughput labs.
Market Cap: Around USD 13 billion.
11. CD Genomics
About: CD Genomics, based in the U.S., provides comprehensive sequencing and bioinformatics services.
Products: Offers specialized RNA-seq services including small RNA and whole transcriptome sequencing.
Market Cap: Private company (market cap undisclosed).
12. Novogene Corporation
About: Novogene, headquartered in China, is a global leader in NGS services and solutions.
Products: Provides cost-effective RNA sequencing services for academic and pharmaceutical research.
Market Cap: Private company (market cap undisclosed).
13. Eurofins Genomics
About: Eurofins Genomics is part of Eurofins Scientific, a global leader in bioanalytical testing.
Products: Offers RNA-seq services and custom solutions for transcriptomics studies.
Market Cap: Parent company Eurofins Scientific valued at USD 15 billion.
14. Fulgent Genetics
About: A U.S.-based company providing comprehensive genetic testing services.
Products: Specializes in NGS-based RNA and DNA testing for clinical and research applications.
Market Cap: Approximately USD 500 million.
Request a customized case study tailored to your business needs and gain deeper insights
into healthcare market strategies: sales@towardshealthcare.com
Frequently Asked Questions (FAQs)
1. What is NGS-based RNA-sequencing?
NGS-based RNA-sequencing (RNA-seq) is a next-generation sequencing method used to study the transcriptome, enabling detection of gene expression levels, mutations, and novel transcripts.
2. Which region dominates the NGS-based RNA-sequencing market?
North America leads the market with a 48% revenue share in 2024, while Asia-Pacific is expected to grow fastest during the forecast period.
3. Who are the top players in the NGS-based RNA-sequencing market?
Key players include Illumina, Thermo Fisher Scientific, Oxford Nanopore Technologies, PacBio, Agilent Technologies, and QIAGEN among others.
4. What is driving the growth of the RNA-sequencing market?
Factors like advancements in sequencing technologies, reduced costs, and rising demand for precision medicine are fueling market growth.
5. What is the projected CAGR for this market?
The global market is expected to grow at a CAGR of 20.1% between 2025 and 2034.
Source : https://www.towardshealthcare.com/insights/ngs-based-rna-sequencing-market-sizing
Invest in Our Premium Strategic Solution: https://www.towardshealthcare.com/price/5886
About the Author
